We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Protein Array Market May Reach $665 Million in ‘07

By Biotechdaily staff writers
Posted on 27 May 2002
The field of drug discovery has been expanded by genomic and proteomic projects, which will increase demand for protein arrays, according to a new analysis from Frost & Sullivan (World Protein Array Markets).

The sale of protein arrays generated worldwide revenues of US$41.2 million in 2001. More...
By 2007, total world revenues for protein array consumables and instruments may surpass $665 million. While a majority of drugs on the market have been based on an estimated 500 proteins, genomic and proteomic efforts have led to a surge of new therapeutic targets. This shifting bottleneck in drug discovery is creating new opportunities for protein arrays that offer more efficient protein-expression analysis and functional characterization.

Despite this promising aspect, suppliers of protein arrays are charged with establishing the value of their product to encourage market adoption. Many participants will need to secure reliable distribution channels to get their products to customers. This may result in some firms forming alliances with larger companies to access supply channels, which could have the effect of diluting their potential earnings.

"Protein arrays promise to provide desired efficiencies by increasing throughput and overcoming inherent limitations with existing research tools,” said Frost & Sullivan analyst Eric. E. Gay. "Nevertheless, competence must be proven prior to adoption since there are significant costs associated with implementing novel technologies.”





Related Links:
Frost & Sullivan

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Electrolyte Analyzer
BKE-B
New
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Alzheimer’s pathology can start 15 to 20 years before symptoms, and validated tools that reach patients earlier help pave the way for earlier detection. (Image Credit: Adobe Stock)

Alzheimer’s Blood Test Becomes First FDA-Cleared Option for Adults as Young as 40

C2N Diagnostics’ PrecivityAD2 blood test was cleared by the U.S. Food and Drug Administration (FDA) on August 20, 2026, for adults as young as 40 who are experiencing signs of cognitive impairment, according... Read more

Pathology

view channel
Image: Adrenal gland tumor stained with hematoxylin and eosin (top) and CYP11B2 (bottom) (Photo courtesy of Christofer Juhlin)

Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism

Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.